<SEC-DOCUMENT>0001193125-22-264856.txt : 20221019
<SEC-HEADER>0001193125-22-264856.hdr.sgml : 20221019
<ACCEPTANCE-DATETIME>20221019062637
ACCESSION NUMBER:		0001193125-22-264856
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20221018
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221019
DATE AS OF CHANGE:		20221019

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zymeworks Inc.
		CENTRAL INDEX KEY:			0001937653
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41535
		FILM NUMBER:		221317193

	BUSINESS ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709
		BUSINESS PHONE:		206-337-1030

	MAIL ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zymeworks Delaware Inc.
		DATE OF NAME CHANGE:	20220712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d399364d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zyme="http://www.zymeworks.com/20221018" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_NoTradingSymbolFlag_duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember" name="dei:NoTradingSymbolFlag" contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">true</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2022-10-18_to_2022-10-18" name="dei:EntityCentralIndexKey" contextRef="duration_2022-10-18_to_2022-10-18">0001937653</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2022-10-18_to_2022-10-18" name="dei:AmendmentFlag" contextRef="duration_2022-10-18_to_2022-10-18">false</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="zyme-20221018.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-10-18_to_2022-10-18"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-18</xbrli:startDate> <xbrli:endDate>2022-10-18</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-18</xbrli:startDate> <xbrli:endDate>2022-10-18</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-18</xbrli:startDate> <xbrli:endDate>2022-10-18</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-10-18_to_2022-10-18">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-10-18_to_2022-10-18" format="ixt:date-monthname-day-year-en">October&#160;18, 2022</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-10-18_to_2022-10-18">Zymeworks Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br /></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:EntityFileNumber">001-41535</ix:nonNumeric></span>&#32;<br /></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:EntityTaxIdentificationNumber">88-3099146</ix:nonNumeric></span>&#32;<br /></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr> </table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:EntityAddressAddressLine1">108 Patriot Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:EntityAddressAddressLine2">Suite A</ix:nonNumeric><br /><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:EntityAddressCityOrTown">Middletown</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br /></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:EntityAddressPostalZipCode">19709</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr> </table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(<ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:CityAreaCode">302</ix:nonNumeric>) <span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18" name="dei:LocalPhoneNumber">274-8744</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-10-18_to_2022-10-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-10-18_to_2022-10-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-10-18_to_2022-10-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-10-18_to_2022-10-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:Security12bTitle">Common Stock, par value $0.00001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:TradingSymbol">ZYME</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember" name="dei:Security12bTitle">Preferred Stock Purchase Rights</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style=" -sec-ix-hidden:Hidden_dei_NoTradingSymbolFlag_duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">N/A</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr> </table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-10-18_to_2022-10-18" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div> <p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">ITEM&#160;1.01</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement.</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;18, 2022, Zymeworks BC Inc. (&#8220;Zymeworks&#8221;), a subsidiary of Zymeworks Inc. (the &#8220;Company&#8221;) entered into a License and Collaboration Agreement (the &#8220;License and Collaboration Agreement&#8221;) with Jazz Pharmaceuticals Ireland Limited (&#8220;Jazz&#8221;), granting Jazz exclusive rights to develop and commercialize Zymeworks&#8217; proprietary bispecific HER2 antibody product candidate known as zanidatamab throughout the world, but excluding the People&#8217;s Republic of China, Australia, New Zealand, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, Hong Kong, Taiwan, Macau, Mongolia, South Korea, Brunei Darussalam, Cambodia, Indonesia, Papua New Guinea, Lao People&#8217;s Democratic Republic, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, and Vietnam (the &#8220;Territory&#8221;). BeiGene, Ltd. has exclusive rights, pursuant to an agreement with Zymeworks dated November&#160;26, 2018, as amended (the &#8220;BeiGene Agreement&#8221;), to commercialize zanidatamab in those countries that are excluded from the Territory.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Licenses</span>. Under the terms of the License and Collaboration Agreement, Zymeworks granted to Jazz an exclusive, royalty-bearing license, with the right to grant sublicenses, under certain of Zymeworks&#8217; intellectual property, to research, develop, manufacture, and commercialize in the Territory pharmaceutical products containing or incorporating zanidatamab or certain related antibodies (such antibodies, collectively, &#8220;Licensed Antibodies&#8221; such pharmaceutical products, &#8220;Licensed Products&#8221;). Licensed Antibodies and Licensed Products expressly exclude all antibody-drug conjugates, including Zymeworks&#8217; proprietary antibody-drug conjugate, zanidatamab zovodotin (also known as ZW49). Zymeworks also granted to Jazz a <span style="white-space:nowrap">non-exclusive</span> license, with the right to grant sublicenses, under certain of Zymeworks&#8217; intellectual property, to research, preclinically develop and manufacture Licensed Products outside the Territory for the sole purpose of furthering the development and commercialization of Licensed Products in the Territory.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jazz granted Zymeworks certain licenses, under certain of Jazz&#8217;s intellectual property, to develop and commercialize Licensed Antibodies and Licensed Products outside the Territory, to conduct certain development and manufacturing activities with respect to the Licensed Products in the Territory, and to make and have made Licensed Antibodies for incorporation into zanidatamab zovodotin, for development and commercialization both in and outside the Territory. If the BeiGene Agreement is terminated, in whole or in part, Jazz has a right of first negotiation to develop or commercialize any Licensed Product in such countries. The licenses granted by Zymeworks and Jazz are effective upon receipt of clearance relating to the United States Hart-Scott Rodino Antitrust Improvements Act of 1976 (such clearance, the &#8220;HSR Clearance&#8221;).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exclusivity</span>. During the Term (as defined below), Jazz and its affiliates are prohibited from performing any clinical development of, or commercialization of, any pharmaceutical product containing a bispecific antibody directed to the ECD2 and ECD4 domains of HER2 in the Territory, other than Licensed Products. During the Term, Zymeworks and its affiliates are prohibited from performing any <span style="white-space:nowrap">pre-clinical</span> development (except for certain independent, internal <span style="white-space:nowrap">pre-clinical</span> development by Zymeworks or its affiliates) or clinical development of, or commercializing, any pharmaceutical product that is directed to HER2 in the Territory (each, a &#8220;Zymeworks Competing Product&#8221;), other than Licensed Products; provided that zanidatamab zovodotin is excluded from this restriction. Zymeworks retains the right to grant third parties rights to apply any of Zymeworks&#8217; platforms to derive or generate, without any assistance from Zymeworks, antibodies directed to any biological target where Zymeworks is not aware of the identity of any such target, and Zymeworks retains the right to fulfill its obligations under agreements with its existing platform partners; provided, however, that Zymeworks cannot generate, or grant development or commercialization licenses to, Zymeworks Competing Products in new platform-based agreements entered into after the effective date of the License and Collaboration Agreement.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Development, Regulatory, Manufacturing, and Commercialization</span>. As between Jazz and Zymeworks, Jazz will be solely responsible for all development and commercial activities with respect to Licensed Products in the Territory, and all such development and commercial activities in the Territory shall be at Jazz&#8217;s sole cost and expense, except that Zymeworks shall be responsible for the continued conduct of clinical trials for zanidatamab initiated by Zymeworks prior to the execution of the License and Collaboration Agreement (collectively, the &#8220;Zymeworks Ongoing Studies&#8221;), including those clinical trials initiated by Zymeworks in South Korea, and filing of the first Biologics License Application for the Licensed Product (the &#8220;First BLA&#8221;), at Jazz&#8217;s cost and expense subject to the terms and conditions under the License and Collaboration Agreement. Following regulatory approval of the First BLA or earlier upon Jazz&#8217;s written request, Zymeworks will promptly transfer the First BLA to Jazz.</p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div></div> <p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jazz shall use commercially reasonable efforts to develop and obtain regulatory approval for a Licensed Product in certain major market countries for the treatment of certain diseases. Jazz will be the holder of regulatory approvals and regulatory submissions for Licensed Products in the Territory, except with respect to the Zymeworks Ongoing Studies, and the First BLA until it is transferred to Jazz.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks will, either itself or through Zymeworks&#8217; contract manufacturing organization, manufacture and Jazz will purchase from Zymeworks, Jazz&#8217;s requirements of zanidatamab and Licensed Product until Jazz or Jazz&#8217;s contract manufacturer is approved to manufacture Licensed Antibody and Licensed Product, or until two years after the closing of the License and Collaboration Agreement (which closing is subject to receipt of the HSR Clearance), whichever is later. Thereafter, Zymeworks will manufacture for Jazz, and Jazz will purchase from Zymeworks, certain quantities of zanidatamab and Licensed Product, until such manufacture is fully transferred to Jazz, but no later than three years after closing. Supply of zanidatamab and Licensed Product shall be further set forth in separate clinical and commercial supply agreements to be executed by the parties.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jazz shall be solely responsible for commercializing the Licensed Products in the Territory and use commercially reasonable efforts to commercialize in each specified major market country each Licensed Product that obtains regulatory approval in such country. Jazz shall conduct such commercialization at its sole cost and expense.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Financial Terms</span>. Jazz has agreed to pay Zymeworks an upfront, <span style="white-space:nowrap">non-refundable</span> payment of $50.0&#160;million, which will be due and payable by Jazz to Zymeworks following receipt of HSR Clearance, and if Jazz decides that it wants to retain its licenses and other rights under the License and Collaboration Agreement, then it will be required to make an additional payment of $325.0&#160;million to Zymeworks within a specified period after the later of (i)&#160;the date on which HSR Clearance is received and (ii)&#160;the date on which Zymeworks delivers to Jazz <span style="white-space:nowrap">top-line</span> data from the locked and cleaned trial database for the Zymeworks ongoing study of zanidatamab in subjects with advanced or metastatic HER2-amplified biliary tract cancers <span style="white-space:nowrap"><span style="white-space:nowrap">(HERIZON-BTC-01),</span></span> known as <span style="white-space:nowrap"><span style="white-space:nowrap">ZWI-ZW25-203,</span></span> as well as all data, analyses and other information set forth in the License and Collaboration Agreement. Jazz&#8217;s failure to make the latter payment before the end of such period shall cause the License and Collaboration Agreement to terminate automatically and immediately. Jazz will reimburse Zymeworks for Zymeworks&#8217; performance of development activities under the License and Collaboration Agreement in accordance with a development plan and budget. Jazz also agreed to pay to Zymeworks potential regulatory milestone payments of up to an aggregate of $525.0&#160;million, and potential commercial milestone payments of up to an aggregate of $862.5&#160;million.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on annual net sales of Licensed Products in the Territory, with customary reductions in specified circumstances. Royalties are payable on a&#160;Licensed <span style="white-space:nowrap"><span style="white-space:nowrap">Product-by-Licensed</span></span>&#160;<span style="white-space:nowrap"><span style="white-space:nowrap">Product&#160;and&#160;country-by-country&#160;basis</span></span> until the latest of (i)&#160;10 years after the first commercial sale of such Licensed Product in such country, (ii)&#160;the expiration of the last valid licensed patent claim within the licensed Zymeworks intellectual property covering such Licensed Product in such country, and (iii)&#160;the expiration of regulatory exclusivity of such Licensed Product in such country.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Intellectual Property</span>. Zymeworks shall solely own all inventions made by the parties solely or jointly that specifically relate to the composition of matter of zanidatamab and any invention made solely by Zymeworks and its affiliates. Jazz shall own all inventions made solely by Jazz. Inventions made jointly by the parties shall be owned jointly by the parties.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Term and Termination</span>. Unless terminated earlier, the term of the License and Collaboration Agreement will continue on a Licensed <span style="white-space:nowrap"><span style="white-space:nowrap">Product-by-Licensed</span></span> Product and <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis until the expiration of the royalty term for such Licensed Product in such country (the &#8220;Term&#8221;).&#160;On a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis, upon the expiration of the Term, the license granted to Jazz in such country shall become fully <span style="white-space:nowrap">paid-up,</span> royalty-free, perpetual, and irrevocable.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time, Jazz may terminate the License and Collaboration Agreement, in its entirety or on a <span style="white-space:nowrap"><span style="white-space:nowrap">region-by-region</span></span> basis, by providing written notice of termination to Zymeworks. In the event that Jazz or its Affiliates file or initiate a patent challenge against Zymeworks, Zymeworks may terminate the License and Collaboration Agreement unless such challenge is withdrawn, abandoned, or terminated following Jazz&#8217;s receipt of written notice from Zymeworks. Subject to certain conditions, either party may terminate the License and Collaboration Agreement in the event of an uncured material breach, insolvency of the other party, or if HSR Clearance is not obtained by a specified date.</p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div></div> <p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the termination of the License and Collaboration Agreement for any reason, all licenses and other rights granted to Jazz by Zymeworks shall terminate.&#160;Licenses granted by Jazz to Zymeworks shall continue following the effective date of termination, and Jazz shall grant to Zymeworks a <span style="white-space:nowrap">non-exclusive,</span> royalty-bearing and sublicensable license under certain intellectual property controlled by Jazz that either arises from the License and Collaboration Agreement or is used by or on behalf of Jazz in the development, manufacture, or commercialization of Licensed Products. If Jazz has the right to terminate the License and Collaboration Agreement because Zymeworks was in material breach of the License and Collaboration Agreement and did not timely cure such breach, Jazz may elect to have the License and Collaboration Agreement continue in full force and effect and all amounts thereafter payable by Jazz under the License and Collaboration Agreement will be reduced, and Jazz will have no further obligations to develop and commercialize each Licensed Product in each major market.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The License and Collaboration Agreement includes certain other customary terms and conditions, including mutual representations and warranties, indemnification, and confidentiality provisions.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the terms of the License and Collaboration Agreement is not complete and is qualified in its entirety by reference to the full text of the License and Collaboration Agreement. A copy of the License and Collaboration Agreement will be filed in redacted form as an exhibit to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022.</p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">ITEM&#160;7.01</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure.</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;19, 2022, the Company and Jazz issued a joint press release regarding the License and Collaboration Agreement. Also, on October&#160;19, 2022, the Company issued a press release regarding the License and Collaboration Agreement. Copies of these press releases are furnished as Exhibits 99.1 and 99.2 to this report and are incorporated herein by reference.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth in this Item 7.01 and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">ITEM&#160;9.01</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits.</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d399364dex991.htm">Joint Press Release dated October&#160;19, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d399364dex992.htm">Zymeworks Press Release dated October&#160;19, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded as Inline XBRL document).</td></tr></table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div></div> <p style="page-break-before:always"></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:44%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ZYMEWORKS INC.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom" colspan="3">(Registrant)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: October&#160;19, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Neil A. Klompas</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Neil A. Klompas</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Operating Officer</td></tr></table></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d399364dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific
Antibody </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Zymeworks to receive $50&nbsp;million upfront payment, a second payment of $325&nbsp;million, at Jazz&#146;s option, and further
potential regulatory and commercial milestones for total potential payments of up to $1.76&nbsp;billion, plus royalties on net sales </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Jazz continues to expand oncology portfolio with novel late-stage asset with compelling anti-tumor activity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">Top-line</FONT> clinical data for zanidatamab in biliary tract cancer <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(HERIZON-BTC-01)</FONT></FONT> expected by end of 2022; potential to support first global regulatory filings </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DUBLIN and
VANCOUVER &#150; October</B><B></B><B>&nbsp;19, 2022 &#150;</B> Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (NYSE: ZYME) today announced that Jazz and Zymeworks&#146; subsidiary, Zymeworks BC Inc., have entered into an exclusive
licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks&#146; zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories
previously licensed by Zymeworks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Zanidatamab is a novel HER2-targeted bispecific antibody with biparatopic binding and the potential to transform
the current standard of care in multiple HER2 expressing cancers,&#148; said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. &#147;This agreement reflects Jazz&#146;s strategic
focus on opportunities where we can not only apply advanced technologies to address critical unmet patient needs, but where we can also leverage Jazz&#146;s existing integrated capabilities and global infrastructure to commercialize efficiently.
Zanidatamab has the potential to deliver significant long-term value and meaningfully contribute to Vision 2025 as we aim to deliver at least five novel therapies to patients by the end of the decade. We are pleased to expand our growing oncology
pipeline with a late-stage program, and today&#146;s announcement further demonstrates our commitment to delivering novel oncology therapies.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In partnering with Jazz, we are thrilled to be working with a leading global biopharmaceutical team that brings a wealth of development and commercial
experience in oncology and shares our vision and passion for working hard every day to improve outcomes for cancer patients around the world,&#148; said Kenneth Galbraith, Chair&nbsp;&amp; CEO of Zymeworks. &#147;Zymeworks and Jazz are committed to
advancing the development of zanidatamab as rapidly as possible, with the potential to provide a foundational HER2-targeted therapy for patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT>
cancers who currently have limited treatment options.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zanidatamab, a HER2-targeted bispecific antibody with novel mechanisms of action, has
demonstrated compelling anti-tumor activity in several HER2-expressing cancers, both as monotherapy and in combination with chemotherapy and other agents. Zanidatamab is currently in pivotal trials as a second-line treatment for HER2-expressing
biliary tract cancer (BTC) and as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA). In BTC, where no HER2-targeted therapies are currently approved, the U.S. Food and Drug Administration (FDA) has granted Breakthrough
Therapy designation for zanidatamab, positioning it as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapy. In GEA, based on Phase 2 data, zanidatamab in combination with chemotherapy
has the potential to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapy. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zanidatamab is based on Zymeworks&#146; Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>
platform and can simultaneously bind two <FONT STYLE="white-space:nowrap">non-overlapping</FONT> epitopes of HER2, which is known as biparatopic binding. This innovative design results in multiple novel mechanisms of action including dual HER2
signal blockade, enhanced binding and removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FDA has granted Breakthrough Therapy designation for zanidatamab in patients with previously treated HER2 gene-amplified BTC, and two Fast Track designations
for zanidatamab, one as a single agent for refractory BTC and one in combination with standard of care chemotherapy, for first-line GEA. These designations mean zanidatamab is eligible for Accelerated Approval, Priority Review and Rolling Review, as
well as FDA guidance on an efficient drug development program. Zanidatamab has also received Orphan Drug designations from FDA for the treatment of biliary tract and gastric cancers, as well as Orphan Drug designation from the European Medicines
Agency for the treatment of gastric cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction Terms </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Jazz will receive an exclusive license to develop and commercialize </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">zanidatamab in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to
BeiGene, Ltd. Zymeworks is eligible to receive a $50&nbsp;million upfront payment, following receipt of the clearance relating to the United States Hart-Scott Rodino Antitrust Improvements Act of 1976 (such clearance, the &#147;HSR Clearance&#148;),
and should Jazz decide to continue the collaboration following readout of the <FONT STYLE="white-space:nowrap">top-line</FONT> clinical data from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-01,</FONT></FONT> a
second, <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $325&nbsp;million. Zymeworks is also eligible to receive up to $525&nbsp;million upon the achievement of certain regulatory milestones and up to $862.5&nbsp;million in potential
commercial milestone payments, for total potential payments of up to $1.76&nbsp;billion.<I> </I>Pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz&#146;s net sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Closing of the agreement is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Act of 1976. The transaction is expected to
close within the 2022 calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks management will host a conference call and webcast for investors and analysts on October&nbsp;19, 2022, at
8:00 a.m. ET. Interested parties should refer to the separate press release issued by Zymeworks for additional details. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zanidatamab </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zanidatamab is a bispecific antibody, based on Zymeworks&#146; Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> platform, that can
simultaneously bind two <FONT STYLE="white-space:nowrap">non-overlapping</FONT> epitopes of HER2, known as biparatopic binding. This unique design results in multiple mechanisms of action including dual HER2 signal blockade, increased binding and
removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2 and pivotal clinical trials globally as a targeted
treatment option for patients with solid tumors that express HER2. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Biliary Tract Cancers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biliary tract cancers (BTC), including gallbladder cancer and cholangiocarcinoma, account for approximately 3% of all adult cancers and are often associated
with a poor prognosis<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>. Globally, more than 210,000 people are diagnosed with BTC every year<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;and most patients (&gt; 65%) are diagnosed
with tumors that cannot be removed surgically. The human epidermal growth factor receptor 2 (HER2) is a well-validated target for anti-cancer therapy. About 5% to 19% of patients with BTC have tumors that express HER2<SUP
STYLE="font-size:75%; vertical-align:top">3</SUP> and may be positioned for potential benefit from HER2-targeted therapy. Currently no HER2-targeted therapy has been approved for the treatment of BTC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Gastroesophageal Adenocarcinoma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gastroesophageal
adenocarcinoma (GEA) is the fifth most common cancer worldwide and approximately 20% of patients are HER2-positive. HER2-positive GEA has high morbidity and mortality, and patients are urgently in need of new treatment options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Jazz Pharmaceuticals plc </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases &#150; often with
limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options
for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75
countries. For more information, please visit <U>www.jazzpharmaceuticals.com</U> and follow @JazzPharma on Twitter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zymeworks Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks&nbsp;is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional
biotherapeutics. Zymeworks&#146; suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks&#146; lead clinical candidate, zanidatamab, is a novel
Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with
solid tumors that express HER2. Zymeworks&#146; second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2 <FONT STYLE="white-space:nowrap">-targeted</FONT> antibody-drug conjugate currently in Phase 1 clinical development
and combines the unique design and antibody framework of zanidatamab with Zymeworks&#146; proprietary ZymeLink<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> linker and cytotoxin.&nbsp;Zymeworks&nbsp;is also advancing a deep preclinical
pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our
ongoing clinical trials visit&nbsp;<U>www.zymeworksclinicaltrials.com</U>. For additional information about&nbsp;Zymeworks, visit&nbsp;<U>www.zymeworks.com</U>&nbsp;and follow&nbsp;<U>@ZymeworksInc</U>&nbsp;on Twitter. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for precision medicine in biliary tract cancers.
Cancer Discov. <FONT STYLE="white-space:nowrap">2017;7(9):943-962.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence,
prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and
meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. <FONT STYLE="white-space:nowrap">2017;36(1):141-157.</FONT> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jazz Pharmaceuticals plc Caution Concerning Forward-Looking Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including, but not limited to, statements related to zanidatamab&#146;s potential to be a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapy in GEA and potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapy in BTC; zanidatamab&#146;s
potential to deliver significant long-term value and meaningfully contribute to Vision 2025; the potential future development, manufacturing, regulatory and commercialization activities; potential future payments by Jazz Pharmaceuticals to Zymeworks
for development, regulatory and commercial milestones as well as tiered royalties based on future net sales; and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals&#146; current plans,
objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of
these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: Jazz Pharmaceuticals&#146; ability to achieve the expected benefits (commercial or otherwise) from the license agreement; pharmaceutical
product development and clinical success thereof; the regulatory approval process; effectively commercializing any product candidates; and other risks and uncertainties affecting Jazz Pharmaceuticals, including those described from time to time
under the caption &#147;Risk Factors&#148; and elsewhere in Jazz Pharmaceuticals plc&#146;s Securities and Exchange Commission filings and reports (Commission <FONT STYLE="white-space:nowrap">File&nbsp;No.&nbsp;001-33500),&nbsp;including</FONT> Jazz
Pharmaceuticals&#146; Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;for</FONT> the quarter ended June&nbsp;30, 2022 and future filings and reports by Jazz Pharmaceuticals. Other risks and uncertainties of which Jazz
Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals&#146; forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are
made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update
or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zymeworks Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes &#147;forward-looking statements&#148; or information within the meaning of the applicable securities legislation, including
Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the
potential therapeutic effects and commercial potential of zanidatamab, zanidatamab zovodotin and Zymeworks&#146; other product candidates; the anticipated benefits of the license agreement with Jazz; Zymeworks&#146; ability to receive the upfront
$50&nbsp;million payment following expiration or termination of the waiting period under the Hart-Scott-Rodino Act and the anticipated timing thereof; Zymeworks&#146; ability to receive additional payments pursuant to the license agreement,
including the additional $325&nbsp;million following readout of the <FONT STYLE="white-space:nowrap">top-line</FONT> clinical data from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-01,</FONT></FONT> as well as any
additional future milestone payments and royalties; the timing of and results of the interactions with regulators; the timing and status of ongoing and future studies and the related data; the commercial potential of zanidatamab and our and Jazz
Pharmaceutical&#146;s ability to obtain regulatory approval of and successfully commercialize zanidatamab the anticipated timing of closing of our agreement with Jazz Pharmaceuticals and satisfactions of closing conditions; and other information
that is not historical information. When used herein, words such as &#147;subject to&#148;, &#147;believes&#148;, &#147;future&#148;, &#147;anticipate&#148;, &#147;approximately&#148;, &#147;will&#148;, &#147;plans&#148;, &#147;may&#148;,
&#147;potential&#148;, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks&#146; current expectations and various assumptions. Zymeworks believes there is a
reasonable basis for its expectations and beliefs, but they </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such
forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks&#146; or its partners&#146; product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a
point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations, including the anticipated upfront payments from Zymeworks&#146; agreement with Jazz; expiration or
termination of the waiting period under the Hart-Scott-Rodino Act may be delayed or may not be received at all; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and
regulations; market conditions; the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Zymeworks&#146; business, research and clinical development plans and timelines and results of operations, including impact on its
clinical trial sites, collaborators, and contractors who act for or on Zymeworks&#146; behalf, may be more severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of Zymeworks&#146; or its
collaborators&#146; product candidates; any of Zymeworks&#146; or its partners&#146; product candidates; Jazz may decide not to proceed with the collaboration following readout of the <FONT STYLE="white-space:nowrap">top-line</FONT> clinical data
from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-01;</FONT></FONT> Zymeworks may be unable to maintain or enter into new partnerships or strategic collaborations and the factors described under &#147;Risk
Factors&#148; in Zymeworks&#146; quarterly and annual reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for its quarter ended June&nbsp;30, 2022 (a copy of
which may be obtained at www.sec.gov and www.sedar.com). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zymeworks believes that such forward-looking statements are reasonable, there can be no
assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and,
except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jazz Media Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristin Bhavnani </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Head of Global Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jazz Pharmaceuticals plc
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CorporateAffairsMediaInfo@jazzpharma.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ireland +353 1 637
2141 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. +1 215 867 4948&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jazz Investor Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrea N. Flynn, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Head, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jazz Pharmaceuticals
plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investorinfo@jazzpharma.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ireland, +353 1 634 3211
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. +1 650 496 2717 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zymeworks Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diana Papove </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Manager, Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@zymeworks.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604)
<FONT STYLE="white-space:nowrap">678-1388</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zymeworks Investor Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jack Spinks </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Associate Director, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@zymeworks.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604)
<FONT STYLE="white-space:nowrap">678-1388</FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d399364dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g399364g85e59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Jazz Pharmaceuticals to obtain exclusive development and commercialization rights in key markets including
the U.S., Europe and Japan </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Zymeworks to receive $50</I><I></I><I>&nbsp;million upfront payment, a second payment of
$325</I><I></I><I>&nbsp;million, at Jazz&#146;s option, and further potential regulatory and commercial milestones for total potential payments of up to $1.76</I><I></I><I>&nbsp;billion</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Webcast beginning today at 8:00 am Eastern Standard Time (EST)</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VANCOUVER, British Columbia &#150; October</B><B></B><B>&nbsp;19, 2022</B> &#151; Zymeworks Inc. (&#147;Zymeworks&#148; or the &#147;Company&#148;) (NYSE:
ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will host a conference call and webcast to discuss that Zymeworks has entered into an exclusive licensing agreement for
zanidatamab, a HER2-targeted bispecific antibody developed using Zymeworks&#146; proprietary Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> platform, with Jazz Pharmaceuticals plc (NASDAQ:JAZZ). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call for Investors and Analysts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks
management will host a conference call and webcast for investors and analysts on October&nbsp;19 at 8:00 am EST. The event will be webcast live with <FONT STYLE="white-space:nowrap">dial-in</FONT> details and webcast replays available on
Zymeworks&#146; website at <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">http://ir.zymeworks.com/events-and-presentations</FONT></FONT></U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zanidatamab </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zanidatamab is a bispecific antibody,
based on Zymeworks&#146; Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> platform, that can simultaneously bind two <FONT STYLE="white-space:nowrap">non-overlapping</FONT> epitopes of HER2, known as biparatopic binding. This
unique design results in multiple mechanisms of action including dual HER2 signal blockade, increased binding, and removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients.
Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zymeworks Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional
biotherapeutics. Zymeworks&#146; suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks&#146; lead clinical candidate, zanidatamab, is a novel
Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with
solid tumors that express HER2. Zymeworks&#146; second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2 targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and
antibody framework of zanidatamab with Zymeworks&#146; proprietary ZymeLink<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including
immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit
<U>www.zymeworksclinicaltrials.com</U>. For additional information about Zymeworks, visit <U>www.zymeworks.com</U> and follow <U>@ZymeworksInc on</U> Twitter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes &#147;forward-looking statements&#148; or information within the meaning of the applicable securities legislation, including
Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the
potential therapeutic effects and commercial potential of zanidatamab, zanidatamab zovodotin and Zymeworks&#146; other product candidates; Zymeworks&#146; clinical development of its product candidates and enrollment in its clinical trials;
anticipated clinical data presentations; Zymeworks&#146; ability to achieve milestones and receive payments from Jazz pursuant to the agreement; and other information that is not historical information. When used herein, words such as
&#147;believes&#148;, &#147;future&#148;, &#147;anticipate&#148;, &#147;approximately&#148;, &#147;will&#148;, &#147;plans&#148;, &#147;may&#148;, &#147;potential&#148;, and similar expressions are intended to identify forward-looking statements. In
addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All
forward-looking statements are based upon Zymeworks&#146; current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its
expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: the impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Zymeworks&#146; business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act
for or on Zymeworks&#146; behalf, may be more severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of Zymeworks&#146; or its collaborators&#146; product candidates; any of
Zymeworks&#146; or its partners&#146; product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive
additional payments under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; inability to maintain or enter
into new partnerships or strategic collaborations and the factors described under &#147;Risk Factors&#148; in Zymeworks&#146; quarterly and annual reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for its quarter ended June&nbsp;30, 2022 (a copy of which may be obtained at www.sec.gov and www.sedar.com). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance
they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may
be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor inquiries: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jack Spinks </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Associate Director, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@zymeworks.com
</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT STYLE="white-space:nowrap">678-1388</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media inquiries: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diana Papove </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Manager, Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>media@zymeworks.com
</U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT STYLE="white-space:nowrap">678-1388</FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>zyme-20221018.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 70.0.8 -->
<!-- Creation date: 10/18/2022 2:48:56 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:zyme="http://www.zymeworks.com/20221018"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.zymeworks.com/20221018"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20221018_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20221018_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20221018_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="zyme_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="zyme_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>zyme-20221018_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 70.0.8 -->
<!-- Creation date: 10/18/2022 2:48:58 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="zyme-20221018.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="zyme-20221018.xsd#zyme_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="zyme-20221018.xsd#zyme_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightsMember" xlink:type="locator" xlink:label="us-gaap_RightsMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="zyme_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="zyme_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RightsMember" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="39.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="43.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="46.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="47.001" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>zyme-20221018_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 70.0.8 -->
<!-- Creation date: 10/18/2022 2:48:57 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">No Trading Symbol Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No Trading Symbol Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="zyme-20221018.xsd#zyme_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zyme_DocumentAndEntityInformationTable" xlink:to="zyme_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="zyme_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="zyme_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="zyme-20221018.xsd#zyme_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="zyme_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="zyme_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="zyme_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, par value $0.00001 per share [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, par value $0.00001 per share [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightsMember" xlink:type="locator" xlink:label="us-gaap_RightsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightsMember" xlink:to="us-gaap_RightsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Purchase Rights [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Purchase Rights [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>zyme-20221018_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 70.0.8 -->
<!-- Creation date: 10/18/2022 2:48:57 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="zyme-20221018.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="zyme-20221018.xsd#zyme_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="zyme_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="zyme-20221018.xsd#zyme_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="zyme_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationTable" xlink:to="zyme_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightsMember" xlink:type="locator" xlink:label="us-gaap_RightsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RightsMember" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="zyme_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g399364g85e59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g399364g85e59.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MK=OL?/>@_M;Z3>:K':Z[X5N-)TR:58UU"TU$:C+:JQVB2YM#9P%XQD,QB=V
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MMZKK9Z7]3V #' X X '&,=.*_2]O*QV[>5@H * "@ H * "@ H * "@ H *
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M2T*:O*^\?5?E:YP(_:?^%_F^5YNO !MOFG2D\KKC=_Q][MO_  '/M7QZ\?.
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M7LEE<9*',^7F]K:_+>U_.Q]9:]XAT+PMI=SK7B+5K#1-)LUW7%_J5S%:VT0
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M9M6]KR.*<JD5\#O:-V[/IQ87+*>'J*K*7/.'P]D^]NZZ=CZ/K]Q/4"@ H *
J"@ H * "@ H * "@ Z=.W]* "@ H * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139645647351952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 18, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zyme_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 18,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zymeworks Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-3099146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Patriot Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Middletown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-8744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001937653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.00001 per share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zyme_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZYME<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RightsMember', window );">Preferred Stock Purchase Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_zyme_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Preferred Stock Purchase Rights<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_zyme_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">zyme_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>zyme_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d399364d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zyme-20221018.xsd" xlink:type="simple"/>
    <context id="duration_2022-10-18_to_2022-10-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
        </entity>
        <period>
            <startDate>2022-10-18</startDate>
            <endDate>2022-10-18</endDate>
        </period>
    </context>
    <context id="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-18</startDate>
            <endDate>2022-10-18</endDate>
        </period>
    </context>
    <context id="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-18</startDate>
            <endDate>2022-10-18</endDate>
        </period>
    </context>
    <dei:NoTradingSymbolFlag
      contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember"
      id="Hidden_dei_NoTradingSymbolFlag_duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">true</dei:NoTradingSymbolFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-10-18_to_2022-10-18"
      id="Hidden_dei_EntityCentralIndexKey_duration_2022-10-18_to_2022-10-18">0001937653</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="duration_2022-10-18_to_2022-10-18"
      id="Hidden_dei_AmendmentFlag_duration_2022-10-18_to_2022-10-18">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="duration_2022-10-18_to_2022-10-18">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-10-18_to_2022-10-18">2022-10-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-10-18_to_2022-10-18">Zymeworks Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-10-18_to_2022-10-18">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-10-18_to_2022-10-18">001-41535</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-10-18_to_2022-10-18">88-3099146</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-10-18_to_2022-10-18">108 Patriot Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-10-18_to_2022-10-18">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-10-18_to_2022-10-18">Middletown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-10-18_to_2022-10-18">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-10-18_to_2022-10-18">19709</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-10-18_to_2022-10-18">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-10-18_to_2022-10-18">274-8744</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-10-18_to_2022-10-18">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-10-18_to_2022-10-18">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-10-18_to_2022-10-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-10-18_to_2022-10-18">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">ZYME</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">Preferred Stock Purchase Rights</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="duration_2022-10-18_to_2022-10-18_us-gaap-StatementClassOfStockAxis_us-gaap-RightsMember">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-10-18_to_2022-10-18">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( %$S4U5ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !1,U-5)!Z;HJT   #X 0
M&@              @ %3$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !1,U-599!YDAD!  #/ P  $P              @ $X$P
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  ""%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d399364d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d399364d8k.htm">d399364d8k.htm</File>
    <File>d399364dex991.htm</File>
    <File>d399364dex992.htm</File>
    <File>zyme-20221018.xsd</File>
    <File>zyme-20221018_def.xml</File>
    <File>zyme-20221018_lab.xml</File>
    <File>zyme-20221018_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d399364d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "zyme-20221018_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d399364d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "zyme-20221018_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zyme-20221018_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "zyme-20221018.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 31,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "zyme",
   "nsuri": "http://www.zymeworks.com/20221018",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d399364d8k.htm",
      "contextRef": "duration_2022-10-18_to_2022-10-18",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d399364d8k.htm",
      "contextRef": "duration_2022-10-18_to_2022-10-18",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag",
        "terseLabel": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.00001 per share [Member]",
        "terseLabel": "Common Stock, par value $0.00001 per share [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Purchase Rights [Member]",
        "terseLabel": "Preferred Stock Purchase Rights [Member]"
       }
      }
     },
     "localname": "RightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "zyme_DocumentAndEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationLineItems",
     "nsuri": "http://www.zymeworks.com/20221018",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "zyme_DocumentAndEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationTable",
     "nsuri": "http://www.zymeworks.com/20221018",
     "presentation": [
      "http://www.zymeworks.com//20221018/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-22-264856-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-264856-xbrl.zip
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M\%@#/S/9P<+E-/;3)G/KV>M4=I]3.I_'/Y,#BN;CN]Y\>RE_@WWOE/1FQ\9
M'<!*\(^%F/"M%O?DV!\XL!:]F];S&^G&D\%V>TOZNU9;3XSBW2E78^FW\/.
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MM >P%ZQ M-[K7:9+QD2,%!M*<_#88;\<7_09#H-W0&(C-P$PXT"'$H_DL\\
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M09YQ.W%M+E#(!2X[#:[):]%2VW^%4HNR"UWSJ88Q]IS,!.9EHHG#%3G59BS
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M&YP9<Z!ID,)9TZ#LH6$((5X I)_=17J7U6EA("G/$>8A5F0Z$I&0%^.> -%
M6-&UJI5H46($X%'?,*2#.M!A:F[_M=5M=S6L@G5XI-:U@DHMKIMH?08O$1\
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MN4%S'U^?'"Y@B'M)Q#<_S'DX<\!C6/*)TT;*%E)14AFNS'ASEUY48;-8IC.
M;=O<R%5_V&"ZN%[@GBO7"=W&8NYU38;31#S?+V;;4<R"JN:P0R=\=H25,RZ2
MCQ\5 JI!0(*B4^)(;AN[E^N%CJ?MG(LH-CD)>V0;D7B< Q4EW"M&A05XEKS@
M A/]R,U<IMM:@Q_F</UQK*H$RTT2W:B&I&1A;LXQTB%8[A,L.#3O8W_YK@;=
MIV(/F6->D^C#)A Y/K=(Z72?H#51Z!U-;8])PF@1A(6IS9AQA^DJ!E':2<^+
M>?C\.@99LM#J] <;&W-LDA+%;&I,PGO)NTYIGE\[6+4=%G#247#=7JE/+5?7
M8.A:;2[6'1&$L++\W (J;M1M-[:;NFH&A%XT)B4,K!.F<SEBFPP!%WTRR32\
M2H9:;UUE,"V4E-NB!P]-3X\N?[A*JMMXI@MRM*X&+.6A'A5C+&*>VW.AA2%0
MN0_+0T5H9@>\#:?&\7>[57<U^E+G/W7K\24F%S]RY3\W)T5I)2K*E3X*&"Y6
M)7*IUHU<*6A4?;+^[#.7UA1?RQ2:0\?F-A)]6(?*7]A.Y_=W6O8?87(T7'V3
MF'S?YF:OL[V]L[FYX9F,GV6(M?BT\'9KL=3]1]>*(CK=P1>IW&L5238Q_8Z;
MG?_HGZ!OCH<1I@9%A^ZQ$S^5L5GV]J:YZ$1?2L0&<1%7EACKKGB[4EA@-NI[
M1N9HIH0S&57GX.8M64MJD]!)4I:U55JZRJR8A@M?EJ1Z]S1OY&#O:=MTV\J*
M%9"D0E!!$L"\#)2Y=Z(ZCD$Z)[0ZD^5H_B*WUZ9H(UJLG,KCY8N07Y^RRZ&+
M8]1OI>8KSRYO9!AQ*6>9ZZ7V0RH[J$'.)23'FG47O\$*7,A/BG92) -@:HT!
MP,<R)3K@R#*^%BA2QJA-5_&,.[WYEH^9+?.XT-NH:QIYU3OG":W?7!TE*AJ.
MTI(B_##SRPD=X/)554T)J>=X6!A3Q-LB'>%=S7NPBV66+K!XC%:+NB)J8@<*
M*]\ 9L%DC+#$KPLAODD%=4$$8?QU;@S\<G8:<\\]WG76WNE7-[BV:K"'9$$6
M2:SSVN)':A3FD9&3R@(C@E!<1]7&;VNW;T=QG$753;^]S:?1Y(2-IDY--=_O
MG2UXOW(T]4#/W(&ZU>XLD"6F<1GS=%QEH>B2V(I%6@=8I@3=B!^<Q('&!_DL
MC*X?;E;2EE4/%]U:I75M$<#@+7/P806C#"/GH%)]N<GAW#0.1JN.AU"94!^M
M:K?F#EW9TSCU<:1O?0[#.A:71N-D*N1V#S*<XE45,*5EEI=2WTBSD%4(&IJ7
M+3JCS!T^^G]^)*L.\.!0J(^OHM1XA?GS2AK0V#CP<,;_:[2CT8%A!$56F6[+
M-S7."F\W7^<C<5#!DE^U=4P'4N4%-D75L,,F0(AAA^:XW)T**.Q-2/86FEE
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M<*9_N@PN+EE /-Z>_H(O^5_ _!]02P,$%     @ 43-35:+FOC>:#@  5C$
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M5+T5]A$2?(3;^EHR%NRFV6O663?5*A96SGL>\P@1=VXCSOH(_[FF_U#,K,:
M?T+P;Q2"<_Q"W&GA"0JW'_>V;$Q06-@?SF[(#"C6TGBHL0J+^8PBLLXX,\)3
MB*?L#2!M?>W'W9V]1Z1@5L(H <@Y^\>&J3AQKR%GF&K$JV:Q2B .80[51FG
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M9"EIM/\<"A4[L;[V)R*+=)<5W7FN.^IIEI9Y(E:@IM=OLC[2"X&1KS<0A=R
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M7[0(B =FK!'#7*=CF"D89 J:0L%Y7Z2\5111"'[*]5#P*"L<] @F'&#?J;P
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M)[M1B1Q$QDH3I\%.^>X<MT!O:7!!<4^Q_](6\4K^0\ OA?1K*Y(R&+PW_#V
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M'#^:DL_/F9R>S)F&E*?$I%36\^@2967)Y50U6[CIBCQM*WT$4^('=\ITII6
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M'YIF9\P_\[-)7?(_4$L! A0#%     @ 43-35>&VZ&95'P  <+(   X
M         ( !     &0S.3DS-C1D.&LN:'1M4$L! A0#%     @ 43-35<[.
M\EA$'@  "',  !$              ( !@1\  &0S.3DS-C1D97@Y.3$N:'1M
M4$L! A0#%     @ 43-35:+FOC>:#@  5C$  !$              ( !]#T
M &0S.3DS-C1D97@Y.3(N:'1M4$L! A0#%     @ 43-35?X7;:2X P  + X
M !$              ( !O4P  'IY;64M,C R,C$P,3@N>'-D4$L! A0#%
M  @ 43-3506Q,-#=!0  '3@  !4              ( !I%   'IY;64M,C R
M,C$P,3A?9&5F+GAM;%!+ 0(4 Q0    ( %$S4U41!O)$)0@  $I<   5
M          "  ;16  !Z>6UE+3(P,C(Q,#$X7VQA8BYX;6Q02P$"% ,4
M" !1,U-5V=#6O88%  "7.P  %0              @ $,7P  >GEM92TR,#(R
B,3 Q.%]P<F4N>&UL4$L%!@     '  < P@$  ,5D      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
